Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement

© 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC..

This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID-19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID-19 (first hospitalization) were identified in the IBM Explorys® electronic health records database. Demographics, baseline clinical characteristics, and in-hospital medications were assessed. For evaluation of in-hospital medications, results were stratified by race, geographic region, age, and month of admission. Of 6564 hospitalized patients with COVID-19-related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs. 31.8%, respectively), nonsteroidal anti-inflammatory drugs (NSAIDs; 27.1% vs. 34.9%), bronchodilators (19.8% vs. 29.5%), and remdesivir (9.3% vs. 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs. 34.5%, respectively), NSAIDs (19.6% vs. 55.7%), bronchodilators (15.9% vs. 41.3%), and remdesivir (10.6% vs. 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas the use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID-19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Journal of medical virology - Vol. 93, No. 9 (2021), p. 5367-5375

Language:

English

Contributors:

Best, Jennie H
Kong, Amanda M
Kaplan-Lewis, Emma
Brawley, Otis W
Baden, Rachel
Zazzali, James L
Miller, Karen S
Loveless, James
Jariwala-Parikh, Krutika
Mohan, Shalini V

Links:

Volltext

Keywords:

Antiviral agents
Cytokine/chemokine
Disease control
Immune responses
Immunodulators
Inflammation
Journal Article
Research Support, Non-U.S. Gov't
Respiratory tract
SARS coronavirus

Notes:

Date Revised 20.07.2021

published: Print-Electronic

Citation Status In-Process

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1002/jmv.27049

PMID:

33913536

PPN (Catalogue-ID):

NLM32577921X